>
Hexima logo

HXL - Hexima Share Price

A$0.155 0.0  0.0%

Last Trade - 5:55am

Sector
Healthcare
Size
Micro Cap
Market Cap £6.96m
Enterprise Value £-3.98m
Revenue £643k
Position in Universe th / 1911
Bullish
Bearish
Unlock HXL Revenue
Momentum
Relative Strength (%)
1m -11.2%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -26.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2005 2006 2007 2008 2009 2010 2011E 2012E CAGR / Avg
0.54 0.20 0.54 1.16 1.05 1.14 +16.2%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2010, HeximaLtd revenues increased 2% to A$462K. Net loss remained flatat A$3.1M. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Net loss reflects Employee Benefit Expensesdecrease of 47% to A$679K (expense), Patent and LegalExpenses decrease of 49% to A$131K (expense), FinanceIncome increase of 20% to A$627K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

HXL Revenue Unlock HXL Revenue

Net Income

HXL Net Income Unlock HXL Revenue

Normalised EPS

HXL Normalised EPS Unlock HXL Revenue

PE Ratio Range

HXL PE Ratio Range Unlock HXL Revenue

Dividend Yield Range

HXL Dividend Yield Range Unlock HXL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
HXL EPS Forecasts Unlock HXL Revenue
Profile Summary

Hexima Limited (Hexima) is an Australia-based biotechnology company. The Company is engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). The Company is conducting a 132 patient Australian phase IIb clinical trial of HXP124 for onychomycosis. The Company holds granted, long-life patents protecting HXP124 in markets globally.

Directors
Last Annual June 30th, 2010
Last Interim December 31st, 2010
Incorporated July 17, 1997
No. of Shareholders: 779
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 80,059,470
Free Float (0.0%)
Eligible for
ISAs
SIPPs
HXL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for HXL
Upcoming Events for HXL
Frequently Asked Questions for Hexima
What is the Hexima share price?

As of 5:55am, shares in Hexima are trading at A$0.155, giving the company a market capitalisation of £6.96m. This share price information is delayed by 15 minutes.

How has the Hexima share price performed this year?

Shares in Hexima are currently trading at A$0.155 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Hexima price has moved by % over the past year.

What are the analyst and broker recommendations for Hexima?

There are no analysts currently covering Hexima.

When will Hexima next release its financial results?

Hexima is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2011-12-31
What is the Hexima dividend yield?

Hexima does not currently pay a dividend.

Does Hexima pay a dividend?

Hexima does not currently pay a dividend.

When does Hexima next pay dividends?

Hexima does not currently pay a dividend.

How do I buy Hexima shares?

To buy shares in Hexima you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Hexima?

Shares in Hexima are currently trading at A$0.155, giving the company a market capitalisation of £6.96m.

Where are Hexima shares listed? Where are Hexima shares listed?

Here are the trading details for Hexima:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: HXL
What kind of share is Hexima?

We were not able to load our ranking data for Hexima

Is there a Hexima share price forecast 2021?

We were not able to load any forecast data for Hexima.

How can I tell whether the Hexima share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hexima. Over the past six months, the relative strength of its shares against the market has been %. At the current price of A$0.155, shares in Hexima are trading at -7.94% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Hexima PE Ratio?

We were not able to find PE ratio data for Hexima.

Who are the key directors of Hexima?

Hexima's management team is headed by:

Marilyn Anderson - CSO
Robyn Heath - SVP
Hugh Morgan - NED
Justine Heath - CFO
Ross Dobinson - CHM
Adam Hall - COO
Scott Robertson - DRC
Nicole Van der Weerden - DRC
Michael Aldridge - DRC
Justin Yap - DRC
Who are the major shareholders of Hexima?

Here are the top five shareholders of Hexima based on the size of their shareholding:

Yap (Lim Sen) Individual Investor
Percentage owned: 11.25% (14.7m shares)
Caroline House Superannuation Fund Pty. Ltd. Corporation
Percentage owned: 6.33% (8.29m shares)
Growing Bros Ltd. Corporation
Percentage owned: 6.05% (7.92m shares)
Beta Gamma Pty. Ltd. Corporation
Percentage owned: 4.38% (5.74m shares)
Skala (Steven M) Individual Investor
Percentage owned: 4.19% (5.48m shares)
Similar to HXL
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.